Following a weak Q3 17 (hit by a DKK90m charge attributable to miscalculations related to the US Veterans Affairs contract in 2009), Coloplast ended the year on an underwhelming note, with Q4 17 results coming in slightly below consensus expectations (1.3% and 0.4% miss on the top-line and profitability, respectively). On a reported basis, sales grew 6% to DKK3,980m, incorporating an 8% organic and 1% acquisitive expansion (acquisition of Comfort Medical), offset by currency headwinds of 3% (
04 Dec 2017
Chasing top-line growth at the expense of profitability
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Chasing top-line growth at the expense of profitability
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
04 Dec 2017 -
Author:
Jyoti Prakash -
Pages:
5
Following a weak Q3 17 (hit by a DKK90m charge attributable to miscalculations related to the US Veterans Affairs contract in 2009), Coloplast ended the year on an underwhelming note, with Q4 17 results coming in slightly below consensus expectations (1.3% and 0.4% miss on the top-line and profitability, respectively). On a reported basis, sales grew 6% to DKK3,980m, incorporating an 8% organic and 1% acquisitive expansion (acquisition of Comfort Medical), offset by currency headwinds of 3% (